Trial Profile

Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; Spartalizumab (Primary) ; Trametinib (Primary)
Indications Malignant melanoma; Skin cancer
Focus Therapeutic Use
Acronyms ALTER-PATH NeoDT

Most Recent Events

30 Oct 2024 Status changed from completed to discontinued. (Reason the study was stopped: Study stopped due to slow enrollment)
10 Oct 2023 Status changed from active, no longer recruiting to completed.
21 Aug 2023 Planned End Date changed from 30 Jun 2023 to 28 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com